The acquired portfolio consists of 13 ANDAs already approved by the Food and Drug Administration and one pending approval.

As a point of reference, Rytary has 6% market share currently 10 years since its launch. We are very confident in achieving US peak sales of $300 million to $500 million for CREXONT. Our Specialty ...

He added that Amneal expects continued top- and bottom-line growth in 2025, despite the loss of exclusivity for Rytary. Amneal projects 2025 total revenue of $3.0B-$3.1B, driven by double-digit ...

Impax Laboratories and Dr. Reddy’s have settled their patent infringement dispute over Rytary, a medication used to treat Parkinson’s disease. Walgreens’ three core segments—U.S. pharmacy ...

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.

Analysts expect CREXONT to achieve approximately 50% payer coverage by 2025, potentially offsetting the impact of Rytary's anticipated loss of exclusivity in August 2025. 3. Biosimilar Pipeline ...